|
US5095026A
(en)
*
|
1983-02-04 |
1992-03-10 |
University Of Iowa Research Foundation |
Prodrugs of carbonic anhydrase inhibitors
|
|
US5200180A
(en)
*
|
1987-06-26 |
1993-04-06 |
Christian Bannert |
Pharmaceutical composition for the treatment of the human eye
|
|
FR2618333B1
(fr)
*
|
1987-07-20 |
1990-07-13 |
Merck Sharp & Dohme |
Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
|
|
US5843156A
(en)
|
1988-08-24 |
1998-12-01 |
Endoluminal Therapeutics, Inc. |
Local polymeric gel cellular therapy
|
|
US6436425B1
(en)
|
1988-11-16 |
2002-08-20 |
Mdv Technologies, Inc. |
Method and non-gelling composition for inhibiting post-surgical adhesions
|
|
US4911926A
(en)
*
|
1988-11-16 |
1990-03-27 |
Mediventures Inc. |
Method and composition for reducing postsurgical adhesions
|
|
US5034406A
(en)
*
|
1989-09-26 |
1991-07-23 |
Allergan, Inc. |
Method for reducing or maintaining intraocular pressure
|
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
FR2653021A1
(fr)
*
|
1989-10-17 |
1991-04-19 |
Merck Sharp & Dohme |
Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
|
|
FR2653018A1
(fr)
|
1989-10-17 |
1991-04-19 |
Merck Sharp & Dohme |
Composition ophtalmique non solide a base de microparticules de polymere contenant au moins un principe actif en suspension dans un milieu dispersant et procede de preparation de ladite composition.
|
|
US5141928B1
(en)
*
|
1989-12-20 |
1995-11-14 |
Brujo Inc |
Ophthalmic medication
|
|
US5496471A
(en)
*
|
1990-01-08 |
1996-03-05 |
Ciba-Geigy Corporation |
Apparatus for removing components from solutions
|
|
FR2657018A1
(fr)
*
|
1990-01-12 |
1991-07-19 |
Merck Sharp & Dohme |
Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
|
|
US5298260A
(en)
*
|
1990-05-01 |
1994-03-29 |
Mediventures, Inc. |
Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
|
|
US5593683A
(en)
*
|
1990-05-01 |
1997-01-14 |
Mdv Technologies, Inc. |
Method of making thermoreversible polyoxyalkylene gels
|
|
US5252318A
(en)
*
|
1990-06-15 |
1993-10-12 |
Allergan, Inc. |
Reversible gelation compositions and methods of use
|
|
US5346703A
(en)
|
1990-08-07 |
1994-09-13 |
Mediventures, Inc. |
Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
|
|
CA2044878C
(en)
*
|
1990-08-07 |
2000-12-26 |
Tacey X. Viegas |
Thermally reversible and irreversible gels
|
|
FR2665635A1
(fr)
*
|
1990-08-10 |
1992-02-14 |
Merck Sharp & Dohme |
Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
|
|
US5847023A
(en)
*
|
1990-10-26 |
1998-12-08 |
Mdv Technologies, Inc. |
Thermal irreversible gel corneal contact lens formed in situ
|
|
JP2594486B2
(ja)
*
|
1991-01-15 |
1997-03-26 |
アルコン ラボラトリーズ インコーポレイテッド |
局所的眼薬組成物
|
|
US5212162A
(en)
*
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
SG84487A1
(en)
|
1991-04-17 |
2001-11-20 |
Merck & Co Inc |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
|
|
ZA927277B
(en)
*
|
1991-10-02 |
1993-05-19 |
Boston Ocular Res |
Dry eye treatment process and solution.
|
|
US5318780A
(en)
*
|
1991-10-30 |
1994-06-07 |
Mediventures Inc. |
Medical uses of in situ formed gels
|
|
DE69327878T2
(de)
*
|
1993-04-16 |
2000-06-15 |
Wakamoto Pharmaceutical Co., Ltd. |
Unter wärmeeinwirkung reversibel gelierende medizinische zusammensetzung auf wasserbasis
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
US5545617A
(en)
*
|
1993-11-12 |
1996-08-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
|
|
CN1129400A
(zh)
*
|
1994-05-06 |
1996-08-21 |
阿尔康实验室公司 |
维生素e生育酚衍生物在眼科组合物中的应用
|
|
IL114193A
(en)
*
|
1994-06-20 |
2000-02-29 |
Teva Pharma |
Ophthalmic pharmaceutical compositions based on sodium alginate
|
|
US5585398A
(en)
*
|
1994-07-15 |
1996-12-17 |
Ernst; Amy A. |
Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
|
|
US6316443B1
(en)
|
1994-08-04 |
2001-11-13 |
Merck & Co., Inc. |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
|
|
US5827835A
(en)
*
|
1994-08-30 |
1998-10-27 |
Alcon Laboratories, Inc. |
Thermally-gelling emulsions
|
|
DK0725628T3
(da)
*
|
1994-08-30 |
2001-12-27 |
Alcon Lab Inc |
Termisk geldannende lægemiddelindgivelsesvehikler indeholdende celluloseethere
|
|
US5516808A
(en)
*
|
1994-10-27 |
1996-05-14 |
Sawaya; Assad S. |
Topical cellulose pharmaceutical formulation
|
|
US5603929A
(en)
*
|
1994-11-16 |
1997-02-18 |
Alcon Laboratories, Inc. |
Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
|
|
US6165490A
(en)
*
|
1996-04-05 |
2000-12-26 |
Staar Surgical Ag |
Biological material, method of preparing such materials, uses thereof and products made therefrom
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5843470A
(en)
*
|
1995-10-06 |
1998-12-01 |
Mdv Technologies, Inc. |
Method and composition for inhibiting post-surgical adhesions
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
EP1057486A1
(de)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
|
|
US6610292B2
(en)
|
1995-11-22 |
2003-08-26 |
Ista Pharmaceuticals, Inc. |
Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
|
|
US5866120A
(en)
*
|
1995-11-22 |
1999-02-02 |
Advanced Corneal Systems, Inc. |
Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
|
|
US5641532A
(en)
*
|
1995-12-15 |
1997-06-24 |
The Procter & Gamble Company |
Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum
|
|
JP4259613B2
(ja)
|
1996-02-13 |
2009-04-30 |
大日本住友製薬株式会社 |
ガラクトキシログルカンを用いるドラッグ・デリバリー・システム
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
US5888493A
(en)
*
|
1996-12-05 |
1999-03-30 |
Sawaya; Assad S. |
Ophthalmic aqueous gel formulation and related methods
|
|
AU6876498A
(en)
*
|
1997-04-03 |
1998-10-22 |
Point Biomedical Corporation |
Intravesical drug delivery system
|
|
GB9707934D0
(en)
*
|
1997-04-18 |
1997-06-04 |
Danbiosyst Uk |
Improved delivery of drugs to mucosal surfaces
|
|
ATE391492T1
(de)
*
|
1997-07-29 |
2008-04-15 |
Alcon Lab Inc |
Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
|
|
AU725552B2
(en)
*
|
1997-07-29 |
2000-10-12 |
Alcon Laboratories, Inc. |
Conditioning solutions for hard contact lens care
|
|
PT999854E
(pt)
|
1997-07-29 |
2003-12-31 |
Alcon Mfg Ltd |
Sistemas viscoelasticos comutaveis contendo polimeros de galactomanano e borato
|
|
US20040063678A1
(en)
*
|
1997-10-06 |
2004-04-01 |
Bausch & Lomb Incorporated |
Dexamethasone Gel
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6312666B1
(en)
*
|
1998-11-12 |
2001-11-06 |
3M Innovative Properties Company |
Methods of whitening teeth
|
|
US6669927B2
(en)
|
1998-11-12 |
2003-12-30 |
3M Innovative Properties Company |
Dental compositions
|
|
US6312667B1
(en)
*
|
1998-11-12 |
2001-11-06 |
3M Innovative Properties Company |
Methods of etching hard tissue in the oral environment
|
|
EA004050B1
(ru)
*
|
1998-12-11 |
2003-12-25 |
Бакулиш Мафатлал Хамар |
Способ изготовления состава местных бета-блокаторов улучшенного действия
|
|
ATE552260T1
(de)
|
1999-01-25 |
2012-04-15 |
Nat Jewish Health |
Substituierte porphyrine und deren therapeutische verwendung
|
|
ATE243038T1
(de)
|
1999-11-01 |
2003-07-15 |
Alcon Inc |
Pharmazeutische zusammensetzungen ein fluorchinolonantibiotikum und xanthangummi enthaltend
|
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
|
DK1305033T3
(da)
|
2000-07-28 |
2005-01-31 |
Alcon Inc |
Farmaceutiske pæaparater indeholdende tobramycin og xanthangummi
|
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
JP2002154989A
(ja)
*
|
2000-11-14 |
2002-05-28 |
Lion Corp |
眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
|
|
DE60141477D1
(de)
*
|
2000-12-20 |
2010-04-15 |
Alcon Inc |
Intraoculare irrigationslösung mit verbesserten fliesseigenschaften
|
|
US6878694B2
(en)
*
|
2000-12-20 |
2005-04-12 |
Alcon, Inc. |
Ophthalmic irrigating solution adapted for use in lasik surgery
|
|
AU2002232437A1
(en)
*
|
2000-12-20 |
2002-07-01 |
Alcon Universal Ltd. |
Ophthalmic lubricating solution adapted for use in lasik surgery
|
|
US20090258955A1
(en)
*
|
2000-12-20 |
2009-10-15 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
|
US7169755B2
(en)
*
|
2000-12-20 |
2007-01-30 |
Alcon, Inc. |
Solution for removing cataracts via liquefracture
|
|
US7084130B2
(en)
*
|
2001-12-11 |
2006-08-01 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
US20020172712A1
(en)
*
|
2001-03-19 |
2002-11-21 |
Alan Drizen |
Antiemetic, anti-motion sustained release drug delivery system
|
|
EP1439842A4
(de)
*
|
2001-06-01 |
2009-09-02 |
Nat Jewish Med & Res Center |
Oxidantienfänger zur behandlung von diabetes oder zur verwendung bei der transplantation oder induktion von immuntoleranz
|
|
WO2003032983A1
(en)
*
|
2001-06-05 |
2003-04-24 |
Ronald Aung-Din |
Transdermal migraine therapy
|
|
US8329734B2
(en)
|
2009-07-27 |
2012-12-11 |
Afgin Pharma Llc |
Topical therapy for migraine
|
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
|
CA2701551A1
(en)
|
2001-08-10 |
2003-02-20 |
Masahiro Inohara |
Polysaccharide-containing compositions and use thereof
|
|
US20080199524A1
(en)
*
|
2001-08-10 |
2008-08-21 |
Toray Industries, Inc. |
Eyedrops containing particulate agar
|
|
AU2002359301B2
(en)
*
|
2001-10-23 |
2008-07-03 |
Comentis, Inc. |
Beta-secretase inhibitors and methods of use
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
US6620405B2
(en)
|
2001-11-01 |
2003-09-16 |
3M Innovative Properties Company |
Delivery of hydrogel compositions as a fine mist
|
|
WO2003072081A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
|
US7642258B2
(en)
*
|
2002-04-19 |
2010-01-05 |
Allergan, Inc. |
Combination of brimonidine and timolol for topical ophthalmic use
|
|
US7030149B2
(en)
|
2002-04-19 |
2006-04-18 |
Allergan, Inc. |
Combination of brimonidine timolol for topical ophthalmic use
|
|
EP1501511A4
(de)
*
|
2002-05-06 |
2006-06-07 |
Univ Washington |
Verfahren zur behandlung von glaukom und anderen erkrankungen, die durch nos-2 expression vermittelt werden, durch hemmung des egfr-wegs
|
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
|
US20060177430A1
(en)
*
|
2002-12-20 |
2006-08-10 |
Chakshu Research Inc |
Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
|
|
US20060172972A1
(en)
*
|
2002-12-20 |
2006-08-03 |
Chakshu Research Inc |
Formulation and method for administration of ophthalmologically active agents
|
|
US20060166879A1
(en)
*
|
2002-12-20 |
2006-07-27 |
Chakshu Research Inc |
Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
|
|
CA2511217A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Chakshu Research, Inc. |
Ophthalmic formulation for the prevention and treatment of ocular conditions
|
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
|
WO2004112723A2
(en)
|
2003-06-20 |
2004-12-29 |
Ronald Aung-Din |
Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
|
|
CN1878571B
(zh)
*
|
2003-11-10 |
2010-09-08 |
东丽株式会社 |
含有多糖类的组合物及泪液层稳定化滴眼剂
|
|
CA2545947A1
(en)
*
|
2003-12-11 |
2005-07-07 |
Alcon, Inc. |
Ophthalmic compositions containing a polysaccharide/borate gelling system
|
|
US20050129770A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Alcon, Inc. |
Ophthalmic compositions containing a PVA/borate gelling system
|
|
JP4771044B2
(ja)
*
|
2004-09-15 |
2011-09-14 |
大正製薬株式会社 |
粘膜適用液剤
|
|
AU2005286844A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc |
Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
|
|
US7659289B2
(en)
*
|
2004-09-17 |
2010-02-09 |
Comentis, Inc. |
Hydroxyethylene-based β-secretase inhibitors and use thereof
|
|
US20080096859A1
(en)
*
|
2004-10-01 |
2008-04-24 |
Sullivan Kathleen A |
Compositions and Methods for Treating Ophthalmic Diseases
|
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
|
US20070059274A1
(en)
*
|
2004-12-01 |
2007-03-15 |
Bahram Asgharian |
Ophthalmic compositions containing a PVA/borate gelling system
|
|
US7485619B2
(en)
*
|
2005-01-31 |
2009-02-03 |
Yeon Sook KIM |
Antimicrobial agent
|
|
JP2008535863A
(ja)
*
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
β−セクレターゼ活性を阻害する化合物およびその使用方法
|
|
EP1907006A2
(de)
*
|
2005-07-15 |
2008-04-09 |
Chakshu Research, Inc. |
Prävention und behandlung von ophthalmischen komplikationen von diabetes
|
|
US7534795B2
(en)
*
|
2005-10-25 |
2009-05-19 |
Allergan, Inc. |
Compounds and their use related to compositions for treating disease
|
|
AU2006311577B2
(en)
|
2005-11-09 |
2013-02-07 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of medical conditions
|
|
JP2009519962A
(ja)
*
|
2005-12-19 |
2009-05-21 |
コメンティス,インコーポレーテッド |
眼投与用局所メカミルアミン製剤およびその使用
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
KR100802534B1
(ko)
|
2006-06-13 |
2008-02-14 |
주식회사태준제약 |
저자극성 점안제 조성물 및 이의 제조 방법
|
|
EP2038272B8
(de)
|
2006-06-30 |
2013-10-23 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl-pdk1-hemmer
|
|
EP2170283B1
(de)
|
2007-06-22 |
2019-01-09 |
Board of Regents, The University of Texas System |
Bildung eines stabilen submikron-peptids oder von proteinteilchen durch dünnfilm-gefrieren
|
|
MX2010000956A
(es)
*
|
2007-07-26 |
2010-03-01 |
Comentis Inc |
Derivados de isoftalamida que inhiben actividad de beta-secretasa.
|
|
CA2699787A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Comentis, Inc. |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
|
MX2010009857A
(es)
*
|
2008-03-07 |
2010-12-07 |
Sun Pharma Advanced Res Co Ltd |
Composicion oftalmica.
|
|
JP5608644B2
(ja)
|
2008-05-23 |
2014-10-15 |
ナショナル ジューイッシュ ヘルス |
アルキル化種の被爆に関連する損傷の処置方法
|
|
EP2296652B1
(de)
|
2008-06-30 |
2017-11-08 |
Afgin Pharma, Llc |
Topische regionale neuroaffektive therapie
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
WO2010011684A2
(en)
*
|
2008-07-21 |
2010-01-28 |
The Regents Of The University Of California |
Prodrug and fluoregenic compositions and methods for using the same
|
|
CA2737388C
(en)
|
2008-09-15 |
2017-07-11 |
Peter Walter |
Methods and compositions for modulating ire1, src, and abl activity
|
|
JP2010132587A
(ja)
*
|
2008-12-03 |
2010-06-17 |
Teika Seiyaku Kk |
眼科用剤
|
|
US8580947B2
(en)
|
2009-02-05 |
2013-11-12 |
Gene Signal International Sa |
Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
|
|
US8470997B2
(en)
*
|
2009-02-05 |
2013-06-25 |
Gene Signal International Sa |
Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
|
|
EP2398443A2
(de)
*
|
2009-02-20 |
2011-12-28 |
Micro Labs Limited |
Lagerstabiles prostaglandin-produkt
|
|
CA2771190C
(en)
|
2009-08-17 |
2020-01-21 |
Memorial Sloan-Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
|
EP2485589A4
(de)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
Heteroaryl-btk-hemmer
|
|
CA2771822C
(en)
|
2009-09-04 |
2020-08-11 |
Daniel A. Erlanson |
Bruton's tyrosine kinase inhibitors
|
|
US8679511B2
(en)
*
|
2009-10-01 |
2014-03-25 |
Duquesne University of the Holy Spririt |
In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
|
|
EP2485731B1
(de)
|
2009-10-06 |
2016-05-11 |
Millennium Pharmaceuticals, Inc. |
Heterocyclische verbindungen als pdk1-inhibitoren
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
CA2778825C
(en)
|
2009-10-26 |
2018-05-22 |
Sephoris Pharmaceuticals, Llc |
Treatment of sunburn using analgesics and antihistamines
|
|
JP2013510886A
(ja)
|
2009-11-16 |
2013-03-28 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア |
キナーゼ阻害剤
|
|
PL2509940T3
(pl)
|
2009-12-10 |
2015-11-30 |
Univ California |
Środki wiążące amyloidy
|
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
|
DE102010009475B4
(de)
|
2010-02-26 |
2011-11-24 |
F. Holzer Gmbh |
Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
|
|
EP2560966B1
(de)
|
2010-03-30 |
2021-01-06 |
Verseon International Corporation |
Mehrfach substituierte aromatische verbindungen als thrombinhemmer
|
|
WO2011127151A2
(en)
|
2010-04-07 |
2011-10-13 |
Allergan, Inc. |
Combinations of preservatives for ophthalmic compositions
|
|
CA2796041A1
(en)
|
2010-04-07 |
2011-10-13 |
Allergan, Inc. |
Combinations of preservative compositions for ophthalmic formulations
|
|
JP5713791B2
(ja)
*
|
2010-05-12 |
2015-05-07 |
テイカ製薬株式会社 |
眼科用剤
|
|
EP2609933A4
(de)
|
2010-08-27 |
2014-04-09 |
Wakamoto Pharma Co Ltd |
Wässrige zusammensetzung zur verabreichung in die augen
|
|
US8530449B2
(en)
|
2010-09-09 |
2013-09-10 |
Assad S. Sawaya |
Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
|
|
SG10201507554RA
(en)
|
2010-09-13 |
2015-10-29 |
Bev Rx Inc |
Aqueous drug delivery system comprising off - flavor masking agent
|
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
US8865766B2
(en)
|
2011-02-14 |
2014-10-21 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
|
PL2710007T3
(pl)
|
2011-05-17 |
2020-06-01 |
The Regents Of The University Of California |
Inhibitory kinazy
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
US8962831B2
(en)
|
2011-05-17 |
2015-02-24 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
|
AU2012279154A1
(en)
|
2011-07-01 |
2014-02-20 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
WO2013063492A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
ES2711425T3
(es)
|
2012-08-27 |
2019-05-03 |
Allergan Inc |
Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
AU2013312296B2
(en)
|
2012-09-10 |
2017-06-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
WO2014052669A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
CA2900335C
(en)
|
2012-10-22 |
2021-10-26 |
City Of Hope |
Synthetic analogs of epipolythiodioxopiperazines and uses thereof
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
WO2014124458A1
(en)
|
2013-02-11 |
2014-08-14 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases
|
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
|
US9938263B2
(en)
|
2013-03-12 |
2018-04-10 |
The General Hospital Corporation |
Gamma-secretase modulators
|
|
US9295665B2
(en)
|
2013-03-12 |
2016-03-29 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
|
|
JP2016519662A
(ja)
|
2013-03-14 |
2016-07-07 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
K2pチャネルの調節
|
|
AU2014236370C1
(en)
|
2013-03-14 |
2019-01-17 |
City Of Hope |
5-bromo-indirubins
|
|
AU2014236356A1
(en)
|
2013-03-14 |
2015-09-24 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
EP2970141B1
(de)
|
2013-03-15 |
2020-02-26 |
Verseon Corporation |
Halogenpyrazole als thrombinhemmer
|
|
ES2853483T3
(es)
|
2013-03-15 |
2021-09-16 |
Verseon Int Corporation |
Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
CN107056838A
(zh)
|
2013-03-15 |
2017-08-18 |
加利福尼亚大学董事会 |
无环核苷膦酸二酯
|
|
ES2847383T3
(es)
|
2013-03-15 |
2021-08-03 |
Atyr Pharma Inc |
Conjugados de Fc-histidil-ARNt sintetasa
|
|
EP2968361A1
(de)
|
2013-03-15 |
2016-01-20 |
Allergan, Inc. |
Bimatoprost zur verbesserung der leptinproduktion
|
|
CA2904794C
(en)
|
2013-03-15 |
2021-11-23 |
Peter Walter |
Modulators of the eif2alpha pathway
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CA2949048A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
WO2015009742A2
(en)
|
2013-07-15 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
EP3636264A1
(de)
|
2013-08-19 |
2020-04-15 |
The Regents of the University of California |
Verbindungen und verfahren zur behandlung einer epileptischen erkrankung
|
|
JP2016530273A
(ja)
|
2013-08-20 |
2016-09-29 |
シティ・オブ・ホープCity of Hope |
癌を治療するためのhdac8阻害剤
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
EP3080122B1
(de)
|
2013-12-11 |
2018-10-31 |
Biogen MA Inc. |
Zur behandlung von erkrankungen des menschen in der onkologie, neurologie und immunologie geeignete biarylverbindungen
|
|
SG11201604595VA
(en)
|
2013-12-11 |
2016-07-28 |
Biogen Ma Inc |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
US9994573B2
(en)
|
2013-12-23 |
2018-06-12 |
Memorial Sloan-Kettering Cancer Center |
Methods and reagents for radiolabeling
|
|
US9913849B2
(en)
|
2014-01-10 |
2018-03-13 |
Manistee Partners Llc |
Treatment of migraines
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
US10167286B2
(en)
|
2014-02-11 |
2019-01-01 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
WO2015123595A1
(en)
|
2014-02-14 |
2015-08-20 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
KR20160124835A
(ko)
|
2014-02-20 |
2016-10-28 |
알러간, 인코포레이티드 |
베타-클로로시클로펜탄의 친수성 에스테르 프로드럭의 사용에 의해 감소된 중앙 각막 비후
|
|
KR20160117614A
(ko)
|
2014-02-21 |
2016-10-10 |
프린시피아 바이오파마, 인코퍼레이티드 |
Btk 억제제의 염 및 고체 형태
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
KR20160128339A
(ko)
|
2014-03-26 |
2016-11-07 |
시티 오브 호프 |
Brca1-결함 암 또는 내성 암의 치료
|
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
|
WO2015175707A1
(en)
|
2014-05-13 |
2015-11-19 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
|
US9012402B1
(en)
|
2014-06-11 |
2015-04-21 |
James Blanchard |
Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
|
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
|
WO2016018917A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of Califoria |
Compositions and methods of making polymerized nucleic acids
|
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
|
CN113620978A
(zh)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
|
SG11201701957XA
(en)
|
2014-09-15 |
2017-04-27 |
Univ California |
Nucleotide analogs
|
|
BR112017004704A2
(pt)
|
2014-09-17 |
2018-01-23 |
Verseon Corp |
composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質のインヒビター
|
|
US10329284B2
(en)
|
2014-10-02 |
2019-06-25 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
|
US20170368192A1
(en)
|
2014-10-13 |
2017-12-28 |
Symic Ip, Llc |
Luminal vessel coating for arteriovenous fistula
|
|
WO2016061145A1
(en)
|
2014-10-13 |
2016-04-21 |
Symic Biomedical, Inc. |
Synthetic proteoglycans for preventing tissue adhesion
|
|
WO2016065083A1
(en)
|
2014-10-21 |
2016-04-28 |
Symic Biomedical, Inc. |
Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
|
|
EA036269B1
(ru)
|
2014-12-18 |
2020-10-21 |
Принсипиа Биофарма Инк. |
Лечение пузырчатки
|
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
|
EA201791610A1
(ru)
|
2015-01-16 |
2017-12-29 |
Сити Оф Хоуп |
Проникающие в клетку антитела
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
HUE059559T2
(hu)
|
2015-02-25 |
2022-12-28 |
Univ California |
5HT agonisták az epilepsziás rendellenességek kezelésére
|
|
US10532995B2
(en)
|
2015-02-27 |
2020-01-14 |
Verseon Corporation |
Substituted pyrazole compounds as serine protease inhibitors
|
|
WO2016138533A2
(en)
|
2015-02-27 |
2016-09-01 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvanation
|
|
WO2016138479A1
(en)
|
2015-02-27 |
2016-09-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
|
US10383816B2
(en)
|
2015-03-02 |
2019-08-20 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoid combination products
|
|
AU2016226267A1
(en)
|
2015-03-02 |
2017-09-28 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoids
|
|
WO2016161018A1
(en)
|
2015-03-30 |
2016-10-06 |
City Of Hope |
Mechanically interlocking complexes
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
CA2982890C
(en)
|
2015-04-17 |
2023-08-22 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
AU2016253149B2
(en)
|
2015-04-24 |
2022-05-19 |
The Regents Of The University Of California |
Modulators of ROR1-ROR2 binding
|
|
CA2986030A1
(en)
|
2015-05-15 |
2016-11-24 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
EP3307732A1
(de)
|
2015-06-10 |
2018-04-18 |
Biogen MA Inc. |
Formen und zusammensetzungen von biarylinhibitoren der bruton-tyrosinkinase
|
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
JP7073109B2
(ja)
|
2015-07-02 |
2022-05-23 |
シティ・オブ・ホープ |
ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
CN114306627A
(zh)
|
2015-08-06 |
2022-04-12 |
希望之城 |
细胞穿透蛋白-抗体缀合物及其使用方法
|
|
EP3128007A1
(de)
|
2015-08-07 |
2017-02-08 |
Gene Signal International SA |
Sterile emulsion mit einem stabilen phosphorothioat-oligonukleotid
|
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
|
US11124483B2
(en)
|
2015-09-02 |
2021-09-21 |
The Regents Of The University Of California |
HER3 ligands and uses thereof
|
|
US10428048B2
(en)
|
2015-09-04 |
2019-10-01 |
City Of Hope |
Androgen receptor antagonists
|
|
KR102768838B1
(ko)
|
2015-09-17 |
2025-02-14 |
시티 오브 호프 |
Pcna 억제제
|
|
CN108430978B
(zh)
|
2015-09-25 |
2022-11-22 |
路德维格癌症研究所有限责任公司 |
3-羟基-喹唑啉-2,4-二酮衍生物及其作为核酸酶调节剂的用途
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017066349A1
(en)
|
2015-10-13 |
2017-04-20 |
Symic Ip, Llc |
Ve-cadherin binding bioconjugate
|
|
CN108367021A
(zh)
|
2015-10-15 |
2018-08-03 |
希望之城 |
包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
|
|
US11046670B2
(en)
|
2015-10-19 |
2021-06-29 |
Board Of Regents, The University Of Texas System |
Piperazinyl norbenzomorphan compounds and methods for using the same
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
CN119241632A
(zh)
|
2015-10-23 |
2025-01-03 |
Erx制药股份有限公司 |
雷公藤红素的类似物
|
|
CA3002907A1
(en)
|
2015-10-23 |
2017-04-27 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic pdk1 inhibitors for use to treat cancer
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
CN108603037B
(zh)
|
2015-12-10 |
2020-11-17 |
希望之城 |
细胞穿透花青偶联抗体
|
|
US11084795B2
(en)
|
2015-12-24 |
2021-08-10 |
The Regents Of The University Of California |
CFTR regulators and methods of use thereof
|
|
PT3394040T
(pt)
|
2015-12-24 |
2022-03-24 |
Univ California |
Reguladores de cftr e seus métodos de uso
|
|
HK1255468A1
(zh)
|
2016-01-05 |
2019-08-16 |
The Regents Of The University Of California |
苯并噻唑两亲物
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
EP3430017B1
(de)
|
2016-03-17 |
2023-01-25 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von parasitären krankheiten
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
GR1009006B
(el)
|
2016-04-01 |
2017-04-04 |
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
|
|
GR1009040B
(el)
|
2016-04-19 |
2017-05-19 |
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων |
Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
|
|
WO2017189613A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
|
WO2017190107A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TWI844006B
(zh)
|
2016-05-05 |
2024-06-01 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
KR102243775B1
(ko)
|
2016-05-12 |
2021-04-22 |
아나코르 파마슈티칼스 인코포레이티드 |
옥사보롤 에스터 및 이의 용도
|
|
EP3463342B1
(de)
|
2016-05-26 |
2023-09-06 |
The Regents of The University of California |
Kombinationen von östrogenrezeptormodulatoren
|
|
EP3478273A1
(de)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc. |
Modifizierte freisetzungsformulierungen von 2-[3-[4-amino-3-(2-fluor-4-phenoxy-phenyl)pyrazol[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitril
|
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP7214632B2
(ja)
|
2016-07-21 |
2023-01-30 |
バイオジェン エムエー インク. |
ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
|
|
ES2925564T3
(es)
|
2016-07-29 |
2022-10-18 |
Rapt Therapeutics Inc |
Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
|
|
US20180049994A1
(en)
|
2016-08-16 |
2018-02-22 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with caryophyllene
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
EP3512535A4
(de)
|
2016-09-13 |
2020-05-06 |
The Jackson Laboratory |
Gezielte verbesserte dna-demethylierung
|
|
US10822353B2
(en)
|
2016-09-15 |
2020-11-03 |
City Of Hope |
Dithio ETP derivatives
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
WO2018112420A1
(en)
|
2016-12-15 |
2018-06-21 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573971A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-on-derivate und ähnliche verbindungen als kras-g12c-modulatoren zur behandlung von krebs
|
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
EP3573954A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
|
|
US10052343B1
(en)
|
2017-02-03 |
2018-08-21 |
Gene Signal International Sa |
Sterile formulation comprising a stable phosphorothioate oligonucleotide
|
|
HRP20240849T1
(hr)
|
2017-02-03 |
2024-09-27 |
Laboratoires Kôl |
Sterilna emulzija koja sadrži stabilni fosforotioat oligonukleotida
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
KR20200019228A
(ko)
|
2017-06-21 |
2020-02-21 |
미토키닌, 인크. |
신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
|
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
|
US10821075B1
(en)
|
2017-07-12 |
2020-11-03 |
James Blanchard |
Compositions for topical application of a medicaments onto a mammalian body surface
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
WO2019067498A2
(en)
|
2017-09-29 |
2019-04-04 |
Genentech, Inc. |
PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE
|
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
WO2019074962A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES
|
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
|
CN112218869A
(zh)
|
2017-11-02 |
2021-01-12 |
卡里科生命科学有限责任公司 |
整合应激通路的调节剂
|
|
KR20200092332A
(ko)
|
2017-11-02 |
2020-08-03 |
칼리코 라이프 사이언시스 엘엘씨 |
통합된 스트레스 경로의 조절제
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
SG11202004009TA
(en)
|
2017-11-02 |
2020-05-28 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
CA3080964A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
CA3080808A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
CA3080971A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
IL274444B2
(en)
|
2017-11-06 |
2024-06-01 |
Rapt Therapeutics Inc |
Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
|
|
WO2019113311A1
(en)
|
2017-12-06 |
2019-06-13 |
Ludwig Institute For Cancer Research Ltd |
Methods of treating cancer with plk4 inhibitors
|
|
MX2020005927A
(es)
|
2017-12-07 |
2020-10-07 |
Amplyx Pharmaceuticals Inc |
Agentes antifunales derivados de piridina heterociclica sustituida.
|
|
PL3724191T3
(pl)
|
2017-12-15 |
2022-04-25 |
Pyramid Biosciences, Inc. |
Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu
|
|
US11939575B2
(en)
|
2017-12-19 |
2024-03-26 |
City Of Hope |
Modified tracrRNAs gRNAs, and uses thereof
|
|
AU2019209470A1
(en)
|
2018-01-16 |
2020-08-13 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
EP3740206B1
(de)
|
2018-01-16 |
2024-03-06 |
Syros Pharmaceuticals, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
|
SG11202007072RA
(en)
|
2018-01-26 |
2020-08-28 |
Rapt Therapeutics Inc |
Chemokine receptor modulators and uses thereof
|
|
KR20200143376A
(ko)
|
2018-03-13 |
2020-12-23 |
샤이어 휴먼 지네틱 테라피즈 인크. |
혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
|
|
MX2020011344A
(es)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences Inc |
Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
|
|
HRP20230488T1
(hr)
|
2018-05-01 |
2023-08-04 |
Revolution Medicines, Inc. |
C40-, C28- I C-32-VEZANI ANALOZI RAPAMICINA KAO INHIBITORI mTOR
|
|
MX2020011564A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina unidos a c26 como inhibidores de mtor.
|
|
WO2019213611A1
(en)
|
2018-05-04 |
2019-11-07 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
|
WO2019236631A1
(en)
|
2018-06-05 |
2019-12-12 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
US20220133747A1
(en)
|
2018-06-06 |
2022-05-05 |
The Regents Of The University Of California |
Estrogen receptor inhibitors and uses therof
|
|
CA3104507A1
(en)
|
2018-06-21 |
2019-12-26 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
US11771688B2
(en)
|
2018-06-25 |
2023-10-03 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
|
CA3107168A1
(en)
|
2018-08-01 |
2020-02-06 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
US12502391B2
(en)
|
2018-08-15 |
2025-12-23 |
Aiviva Biopharma, Inc. |
Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
KR20210088528A
(ko)
|
2018-08-31 |
2021-07-14 |
앰플릭스 파마슈티컬스, 인크. |
진균 감염을 치료하기 위한 화합물 및 방법
|
|
US12187762B2
(en)
|
2018-09-10 |
2025-01-07 |
The Regents Of The University Of California |
Dithiolsaccharide mucolytic agents and uses thereof
|
|
TWI832295B
(zh)
|
2018-10-11 |
2024-02-11 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
ES2993867T3
(en)
|
2018-11-01 |
2025-01-10 |
Lynk Pharmaceuticals Co Ltd |
Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
|
|
CA3121155C
(en)
|
2018-11-26 |
2023-09-05 |
Aiviva Biopharma, Inc. |
Pharmaceutical biodissolvable gels for drug delivery
|
|
WO2020118683A1
(en)
|
2018-12-14 |
2020-06-18 |
Lynk Pharmaceuticals Co. Ltd. |
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
|
|
MX2021010544A
(es)
|
2019-03-14 |
2021-10-01 |
Calico Life Sciences Llc |
Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
|
|
US20200347043A1
(en)
|
2019-04-30 |
2020-11-05 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
FR3095592B1
(fr)
*
|
2019-05-02 |
2021-05-21 |
Unither Pharmaceuticals |
Composition à base de gomme gellane et de phényléphrine, procédé de fabrication et utilisation comme produit ophtalmique
|
|
EP3968979A4
(de)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
Ketaminformulierung für subkutane injektion
|
|
EP4516300A3
(de)
|
2019-06-14 |
2025-08-06 |
Children's Hospital Medical Center |
Rationales therapeutisches targeting von onkogenen immunsignalisierungszuständen bei myeloiden malignomen über das ubiquitin-konjugierende enzym ube2n
|
|
ES2987744T3
(es)
|
2019-09-18 |
2024-11-18 |
Takeda Pharmaceuticals Co |
Inhibidores de calicreína plasmática y usos de los mismos
|
|
CR20220107A
(es)
|
2019-09-18 |
2022-04-25 |
Novartis Ag |
Proteínas de fusión nkg2d y sus usos
|
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
|
US12516145B2
(en)
|
2019-09-30 |
2026-01-06 |
Northwestern University |
Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
|
|
EP4045051A1
(de)
|
2019-10-14 |
2022-08-24 |
Principia Biopharma Inc. |
Verfahren zum behandeln von immunthrombozytopenie durch verabreichen von (r)-2-[3-[4-amino-3-(2-fluor-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitril
|
|
WO2021087076A1
(en)
|
2019-10-30 |
2021-05-06 |
Northwestern University |
Selenium-containing analogues of pheomelanin and related materials and methods of making
|
|
EP4058456A1
(de)
|
2019-11-13 |
2022-09-21 |
RAPT Therapeutics, Inc. |
Kristalline formen des c-c-chemokinrezeptor-typ-4-agonisten und deren verwendungen
|
|
JP7751582B2
(ja)
|
2019-12-18 |
2025-10-08 |
カリコ ライフ サイエンシーズ エルエルシー |
タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
|
|
PH12022551787A1
(en)
|
2020-01-22 |
2024-02-12 |
Principia Biopharma Inc |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
WO2021198911A1
(en)
|
2020-03-31 |
2021-10-07 |
Sentiss Pharma Private Limited |
A sterilization process of timolol gel forming solution through aseptic filtration
|
|
GR1010024B
(el)
|
2020-05-06 |
2021-06-01 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
|
|
JP7766623B2
(ja)
|
2020-05-19 |
2025-11-10 |
サイビン アイアールエル リミテッド |
重水素化トリプタミン誘導体および使用方法
|
|
KR20230053611A
(ko)
|
2020-08-18 |
2023-04-21 |
사이빈 아이알엘 리미티드 |
펜에틸아민 유도체, 조성물, 및 사용 방법
|
|
CA3194653A1
(en)
|
2020-10-02 |
2022-04-07 |
Mitokinin, Inc. |
Compositions and methods of treating kidney disease and fibrosis
|
|
MX2023005056A
(es)
|
2020-11-02 |
2023-07-24 |
Trethera Corp |
Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos.
|
|
CA3198795A1
(en)
|
2020-11-18 |
2022-05-27 |
Jeffrey Becker |
Complexing agent salt formulations of pharmaceutical compounds
|
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
EP4308229A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasmakallikreinhemmer
|
|
EP4308230A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Heteroaryl-inhibitoren von plasmakallikrein
|
|
WO2022197756A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Plasma kallikrein inhibitors
|
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
|
EP4308564A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclische inhibitoren von plasmakallikrein
|
|
CA3216545A1
(en)
|
2021-04-13 |
2022-10-20 |
Pipeline Therapeutics, Inc. |
Crystalline compound of muscarinic acetylcholine m1 receptor antagonists
|
|
KR20240153566A
(ko)
|
2022-02-15 |
2024-10-23 |
사이빈 아이알엘 리미티드 |
치료적 펜에틸아민 조성물, 및 사용 방법
|
|
US20250145566A1
(en)
|
2022-02-15 |
2025-05-08 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
CN119585256A
(zh)
|
2022-04-06 |
2025-03-07 |
拉普特医疗公司 |
趋化因子受体调节剂及其用途
|
|
US12539305B2
(en)
|
2022-05-25 |
2026-02-03 |
Revolution Medicines, Inc. |
Methods of treating cancer with an mTOR inhibitor
|
|
US12377036B2
(en)
|
2022-06-21 |
2025-08-05 |
Northwestern University |
Melanin hair dye with thickeners
|
|
WO2025015029A1
(en)
|
2023-07-12 |
2025-01-16 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
|
AU2024296743A1
(en)
|
2023-07-13 |
2026-02-26 |
Comanche Biopharma Corp. |
Formulations of nucleic acid compounds and uses thereof
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
WO2025068803A1
(en)
|
2023-09-26 |
2025-04-03 |
Astrazeneca Ab |
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
WO2026022243A1
(en)
|
2024-07-23 |
2026-01-29 |
The Trustees Of The University Of Pennsylvania |
Combination of a gsk-3 inhibitor and a lsd-1 inhibitor for use in the treatment of cancer
|